<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04879069</url>
  </required_header>
  <id_info>
    <org_study_id>276/21</org_study_id>
    <nct_id>NCT04879069</nct_id>
  </id_info>
  <brief_title>Polish Multicenter PERTs PE Outcomes Registry</brief_title>
  <acronym>PolPERTs</acronym>
  <official_title>Polish Multicenter Pulmonary Embolism Response Teams Outcomes Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Polish Cardiac Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Poznan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary embolism (PE) is the third leading cause of cardiovascular mortality. The Pulmonary&#xD;
      Embolism Response Team (PERT) concept offers a rapid and multidisciplinary approach focused&#xD;
      on improving outcomes for patients with PE. All institutionalized PERTs in Poland have been&#xD;
      invited to join the study. The goal of this registry is to describe current practice and&#xD;
      outcomes in patients with acute PE treated by Polish PERTs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary embolism (PE) is the third leading cause of cardiovascular mortality. The&#xD;
      presentation of PE may vary from asymptomatic or mild exertion disturbances (low-risk PE)&#xD;
      treated with anticoagulants only to hemodynamic &quot;obstructive&quot; collapse and death (high-risk&#xD;
      PE). Patient outcome depends on ability of the right ventricle to sustain the increased&#xD;
      afterload caused by the embolic burden. Careful risk stratification is crucial, and the&#xD;
      Pulmonary Embolism Response Team (PERT) concept offers a rapid and multidisciplinary approach&#xD;
      focused on improving outcomes for patients with PE by advancing its recognition, diagnosis,&#xD;
      and treatment. All institutionalized PERTs in Poland have been invited to join the study. The&#xD;
      data is administrated by the Poznan University of Medical Sciences on the basis of an&#xD;
      agreement between the PERT centres.&#xD;
&#xD;
      The goal of this registry is to describe current practice and outcomes in patients with acute&#xD;
      PE guided by Polish PERTs. The primary data recorded include details of each patient's&#xD;
      clinical status, co-morbidities, the administered treatment modalities, the results of&#xD;
      additional studies (ab tests results, ECG, imaging studies), and the outcome.&#xD;
&#xD;
      The data collection will have no impact on the way the patient is diagnosed and treated.The&#xD;
      study endpoints comprise respiratory failure, shock, death distal systemic embolization (i.e.&#xD;
      stroke) and major or minor bleeding complications classified according to the International&#xD;
      Society on Thrombosis and Haemostasis classification.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 2030</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical improvement during hospitalization</measure>
    <time_frame>24 hours after specific PE treatment implementation</time_frame>
    <description>Incidence of arterial blood saturation increase &gt;92%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular strain reduction</measure>
    <time_frame>24 hours after specific PE treatment implementation</time_frame>
    <description>Rate of right ventricular strain reduction (right ventricle/left ventricle ratio assessment) in echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Early mortality rate from pulmonary embolism</measure>
    <time_frame>Two weeks since PE diagnosis</time_frame>
    <description>Number of patients who died from pulmonary embolism (right heart failure)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total mortality rate from pulmonary embolism</measure>
    <time_frame>3 months since PE diagnosis</time_frame>
    <description>Number of patients who died from pulmonary embolism (right heart failure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding events incidence</measure>
    <time_frame>3 months since PE diagnosis</time_frame>
    <description>Incidence of major bleedings assessed using ISTH criteria</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Pulmonary Embolism With Acute Cor Pulmonale</condition>
  <arm_group>
    <arm_group_label>Intermediate-high risk PE</arm_group_label>
    <description>Confirmed PE causing right ventricle dysfunction confirmed by computed tomography pulmonary angiography or transthoracic echocardiography and elevated troponin level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-risk PE</arm_group_label>
    <description>Confirmed PE causing hemodynamic instability:&#xD;
Cardiac arrest (need for cardiopulmonary resuscitation) or,&#xD;
Obstructive shock (systolic blood pressure &lt; 90 mmHg or vasopressors required to achieve a systolic blood pressure ≥90 mmHg despite adequate filling status and end-organ hypoperfusion), or&#xD;
Persistent hypotension (systolic blood pressure &lt; 90 mmHg for at least 15 minutes)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients hospitalized due to high-risk or intermediate-high risk PE.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. PE confirmed by computed tomography pulmonary angiography.&#xD;
&#xD;
          2. PE symptoms duration ≤ 14 days.&#xD;
&#xD;
          3. High-risk PE with hemodynamic instability (one of):&#xD;
&#xD;
               -  cardiac arrest&#xD;
&#xD;
               -  obstructive shock&#xD;
&#xD;
               -  persistent hypotension.&#xD;
&#xD;
          4. Intermediate-high risk PE patients with right ventricle dysfunction confirmed by&#xD;
             imaging studies and elevated troponin level.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Refusal to sign the informed consent form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleksander Araszkiewicz, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poznan University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aleksander Araszkiewicz</last_name>
    <phone>8549146</phone>
    <phone_ext>+48</phone_ext>
    <email>aaraszkiewicz@ump.edu.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sylwia Sławek-Szmyt</last_name>
    <phone>8549293</phone>
    <phone_ext>+48</phone_ext>
    <email>sylwia.slawek@skpp.edu.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Poznan University of Medical Sciences</name>
      <address>
        <city>Poznań</city>
        <state>GreaterPoland</state>
        <zip>61-848</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksander Araszkiewicz, Prof.</last_name>
      <phone>8549149</phone>
      <phone_ext>+48</phone_ext>
      <email>aaraszkiewicz@ump.edu.pl</email>
    </contact>
    <contact_backup>
      <last_name>Sylwia Sławek-Szmyt, MD, PhD</last_name>
      <email>sylwia.slawek@skpp.edu.pl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Poznan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Aleksander Araszkiewicz</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>pulmonary embolism, pulmonary embolism response team,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Heart Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

